Worldwide, each year more than 7 million people experience myocardial infarction, in which
one-year mortality rates are now in the range of 10%, but vary with patient characteristics …

Hypertension, a global public health problem, is currently the leading factor in the global
burden of disease. It is the major modifiable risk factor for heart disease, stroke and kidney …

In 2018, the American Heart Association published a Scientific Statement on resistant
hypertension. We compared the prevalence of apparent treatment-resistant hypertension …

Executive summary Elevated blood pressure is the strongest modifiable risk factor for
cardiovascular disease worldwide. Despite extensive knowledge about ways to prevent as …

Primary aldosteronism (PA) due to a unilateral aldosterone-producing adenoma is a
common cause of hypertension. This can be cured, or greatly improved, by adrenal surgery …

Aims To investigate the effects of spironolactone on fibrosis and cardiac function in people at
increased risk of developing heart failure. Methods and results Randomized, open-label …

Hyperinsulinemia and insulin resistance were proposed more than 30 years ago to be
important contributors to elevated blood pressure (BP) associated with obesity and the …

Hypertension Canada provides annually updated, evidence-based guidelines for the
diagnosis, assessment, prevention, and treatment of hypertension. This year, we introduce …

The aim of this study is to compare spironolactone versus clonidine as the fourth drug in
patients with resistant hypertension in a multicenter, randomized trial. Medical therapy …

Mineralocorticoid receptors (MRs) are implicated in the pathology of hypertension. MR
blockers are recommended for the treatment of salt-sensitive or resistant hypertension …